News

Phosphagenics has initiated Phase 1B clinical trial for its patented Oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems. The primary objective of the Phase 1B clinical trial is to

Shire has settled the litigation with Teva over Shire’s supply to Teva of an authorised generic version of Adderall XR. Shire has been supplying Teva with authorised generic

PTC Therapeutics (PTC) has received $1m challenge grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH). The

Health Enhancement Products (HEPI) has reported that based on observations of ProAlgaZyme (PAZ) activity during tests for inflammation management, Wayne State University School of Medicine professor of pathology

Javelin Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for its investigational product candidate, Dyloject (diclofenac sodium) injection, for the management of acute moderate-to-severe pain

Taris Biomedical (Taris) has reported the completion of Phase 1 clinical study of its intravesical drug-device convergence system designed to provide sustained-release of drug directly to the bladder.

TET Systems (TSH), the Academic Medical Center (AMC), and Technology Foundation STW have entered into an assignment agreement. Scientists at the AMC have previously developed a series of

Ipsen has announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for Taspoglutide.

Ablynx is expected to receive further milestone payments of E3m from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of nanobodies. Ablynx